Conversely,
CD15 was positive in 88% of cHL cases that were negative for CD137.
(A) Genome browser view displays tracks from top: Refseq gene AHRR; CpG Islands; C14+ Monocyte DMRs (black bar); differentially methylated CpGs ([DELTA] Methylation %) in CD14+ monocytes (CD14+ Mono) and
CD15 + granulocytes (
CD15 + Gran), and histone modification data tracks from the Epigenome Roadmap Project(a) for each cell type: H3K4me3, histone H3 Lysine 4 trimethyl (active mark); H3K27ac, histone H3 Lysine 27acetyl (active enhancer); H3K4me1, histone H3 Lysine 4 monomethyl (enhancer); H3K27me3, histone H3 Lysine 27trimethyl (repressive mark).
(a) mRNA expression of eight stem cell markers (Nestin, CXCR4, Oct3/4,
CD15, CD133, Bmi-1, Sox2, and CD44) and four stem cell-related molecules (HIF-1[alpha], HIF-2[alpha], VEGF, and TGF-[beta]) in the core and the periphery was determined with qRT-PCR.
(3-5,7) In the present case the HRS cells were CD30+, CD20+, CD79a+ but
CD15 was negative as may occur in these lymphomas.
Interestingly, besides an increase in neutrophil number, as seen in experimental data from hypercortisolemic conditions [27, 28], the neutrophils of all CS patients showed a tendency to express activation markers like FC receptor CD16 and tetrasaccharide adhesion marker
CD15, an association that persists in multiregression analysis.
Bone marrow biopsy and aspirate showed 73% myeloblasts and immature promonocytes expressing CD13,
CD15, CD33, CD45, CD64, CD123, and HLA-DR by immunohistochemistry (IHC) and flow cytometry (FC).
Reed- Sternberg-like and histiocyte-like cells displayed CD68 (Figure 1D) and Mac387 expression; however, no reaction was determined with
CD15 (LeuM1) and CD30 (Ki-1).
Pericardial biopsy revealed multiple nodules with interstitial hyalineosis containing a polymorphic infiltrate of small lymphocytes, rare eosinophils and Reed-Sternberg cells with CD30 and
CD15 positivity (Figure 2).
strain
cd15 isolated from the tissue of coral Goniastrea aspera, jepara waters.
All cases of lymphoma were CD20 positive, CD5,
CD15, and CD30 negative and the patients were diagnosed with diffuse large B-cell lymphoma [Table 3].
The panel of lymphoid antibodies included: TdT, CD34, CD45, CD19,CD20, CD79, MUM-1 CDI0 ,CD21, CD23, CD3 ,CD4, CD5, CD8,
CD15, CD30, CD43, CD56,CD68, MPO, Ki-67, Bcl-2, Bcl-6, Cyclin D1, Kappa, Lamda, ALK-1, ZAP 17 were used.